MedDataX Logo

Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

NCT ID: NCT03235167

Last Updated: 2017-09-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-31

Study Completion Date

2022-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CpG DNA

CpG DNA concentrate

Group Type EXPERIMENTAL

CpG DNA

Intervention Type DRUG

CpG DNA concentrate

transcatheter arterial chemoembolization

Intervention Type PROCEDURE

transcatheter arterial chemoembolization (TACE) therapy for liver cancer

placebo

placebo concentrate

Group Type PLACEBO_COMPARATOR

transcatheter arterial chemoembolization

Intervention Type PROCEDURE

transcatheter arterial chemoembolization (TACE) therapy for liver cancer

Placebo - Concentrate

Intervention Type DRUG

CpG DNA vehicle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CpG DNA

CpG DNA concentrate

Intervention Type DRUG

transcatheter arterial chemoembolization

transcatheter arterial chemoembolization (TACE) therapy for liver cancer

Intervention Type PROCEDURE

Placebo - Concentrate

CpG DNA vehicle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* TNM (tumor node metastasis ) staging with non distant metastasis; no other tumors

Exclusion Criteria

* having received previous treatment for liver cancer
Minimum Eligible Age

55 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dalian University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

xiaolin Yuan

Role: PRINCIPAL_INVESTIGATOR

Affiliated Zhongshan Hospital of Dalian University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

haoren wang

Role: CONTACT

[email protected]
86-041162893507

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

zsyy_zxsys2017-07

Identifier Type: -

Identifier Source: org_study_id